Metformin and heart failure: never say never again

Bibliography

• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E, Mikhailidis DP. Metformin: diamonds are forever. Expert Opin Pharmacother 2009;10:2395-7
   PubMed Web of Science ®Google Scholar
• Bolen S, Feldman L, Vassy J, Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Fantus IG. Metformin's contraindications: needed for now. CMAJ 2005;173:505-7
   PubMed Web of Science ®Google Scholar
• Papanas N, Monastiriotis C, Christakidis D, Maltezos E. Metformin and lactic acidosis in patients with type 2 diabetes─ from pride and prejudice to sense and sensibility. Acta Clin Belg 2009;64:42-8
   PubMed Web of Science ®Google Scholar
• Fisman EZ, Tenenbaum A, Motro M, Adler Y. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint. Herz 2004;29:290-8
   PubMed Web of Science ®Google Scholar
• McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 2005;173:502-4
   PubMed Web of Science ®Google Scholar
• Holstein A, Stumvoll M. Contraindications can damage your health–is metformin a case in point? Diabetologia 2005;48:2454-9
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ 2007;335:508-12
   PubMed Web of Science ®Google Scholar
• Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-8
   PubMed Web of Science ®Google Scholar
• McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008;10:703-8
   PubMed Web of Science ®Google Scholar
• Casscells SW, Granger E, Swedorske J, A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006. Am J Ther 2008;15:198-205
   PubMed Web of Science ®Google Scholar
• Tzoulaki I, Molokhia M, Curcin V, Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Kattan MW, Yu C, The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009;46:145-54
   PubMed Web of Science ®Google Scholar
• Eurich DT, Majumdar SR, McAlister FA, Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51
   PubMed Web of Science ®Google Scholar
• Masoudi FA, Inzucchi SE, Wang Y, Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583-90
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Masoudi FA, Wang Y, Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005;28:1680-9
   PubMed Web of Science ®Google Scholar
• Karter AJ, Ahmed AT, Liu J, Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22:986-93
   PubMed Web of Science ®Google Scholar
• Eurich DT, McAlister FA, Blackburn DF, Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497
   PubMed Web of Science ®Google Scholar
• MacDonald MR, Eurich DT, Majumdar SR, Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010;33:1213-18
   PubMed Web of Science ®Google Scholar
• Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010;16:200-6
   PubMed Web of Science ®Google Scholar
• Andersson C, Olesen JB, Hansen PR, Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010;53:2546-53
   PubMed Web of Science ®Google Scholar
• Roussel R, Travert F, Pasquet B, Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9
   PubMed Web of Science ®Google Scholar
• Evans JM, Doney AS, AlZadjali MA, Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 2010;106:1006-10
   PubMed Web of Science ®Google Scholar
• Aguilar D, Chan W, Bozkurt B, Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011;4:53-8
   PubMed Web of Science ®Google Scholar
• Boyd A, Nawarskas J. Metformin use in decompensated heart failure. Cardiol Rev 2008;16:269-72
   PubMedGoogle Scholar
• Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011;118:c380-3
   PubMed Web of Science ®Google Scholar
• Khurana R, Malik IS. Metformin: safety in cardiac patients. Postgrad Med J 2010;86:371-3
   PubMedGoogle Scholar
• Gundewar S, Calvert JW, Jha S, Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009;104:403-11
   PubMed Web of Science ®Google Scholar
• Sasaki H, Asanuma H, Fujita M, Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009;119:2568-77
   PubMedGoogle Scholar
• Calvert JW, Gundewar S, Jha S, Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signalling. Diabetes 2008;57:696-705
   PubMed Web of Science ®Google Scholar
• Yin M, van der Horst IC, van Melle JP, Metformin improves cardiac function in a non-diabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol 2011;301:H459-68
   Google Scholar
• Xie Z, Lau K, Eby B, Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 2011;60:1770-8
   PubMed Web of Science ®Google Scholar
• Wang XF, Zhang JY, Li L, Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clin Exp Pharmacol Physiol 2011;38:94-101
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
   PubMed Web of Science ®Google Scholar
• Xiao H, Ma X, Feng W, Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res 2010;87:504-13
   PubMed Web of Science ®Google Scholar
• Bujak M, Ren G, Kweon HJ, Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 2007;116:2127-38
   PubMed Web of Science ®Google Scholar
• Forcheron F, Basset A, Abdallah P, Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model─ the Zucker diabetic rat. Cardiovasc Diabetol 2009;8:16
   PubMedGoogle Scholar
• Muntoni S. Metformin and heart failure: innocent until proven guilty. Diabetes Care 2006;29:751-2
   PubMedGoogle Scholar
• Fischer Y, Thomas J, Rosen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology 1995;136:412-20
   PubMed Web of Science ®Google Scholar
• Eurich DT, Tsuyuki RT, Majumdar SR, Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials 2009;10:12
   PubMed Web of Science ®Google Scholar
• Shenoy C. Metformin-associated lactic acidosis precipitated by acute renal failure. Am J Med Sci 2006;331:55-7
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure. Diabetes Care 2007;30:e129
   Google Scholar
• Eurich DT, Majumdar SR, McAlister FA, Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches. Open Med 2010;4:e40-8
   Google Scholar
• Canadian Diabetes Association. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diab 2008;32(Suppl 1):S1-S200
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care 2011;34(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Weiss SR. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf 2005;14:697-703
   PubMedGoogle Scholar
• Maru S, Koch GG, Stender M, Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 2005;28:20-6
   PubMed Web of Science ®Google Scholar
• Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra-indications to metformin therapy are largely disregarded. Diabet Med 1999;16:692-6
   PubMed Web of Science ®Google Scholar
• Horlen C, Malone R, Bryant B, Frequency of inappropriate metformin prescriptions. JAMA 2002;287:2504-5
   PubMed Web of Science ®Google Scholar
• Masoudi FA, Wang Y, Inzucchi SE, Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003;290:81-5
   PubMedGoogle Scholar